Amneal Pharmaceuticals (AMRX) Misses Q2 EPS by 1c; Offers FY22 Guidance

Amneal Pharmaceuticals (: AMRX) reported Q2 EPS of $0.19, $0.01 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $559 million versus the consensus estimate of $534.44 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2022 EPS of $0.65-$0.70, versus the consensus of $0.81. Amneal Pharmaceuticals sees FY2022 revenue of $2.15-2.25 billion, versus the consensus of $2.17 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Worthington Industries (WOR) Misses Q4 EPS by 9c
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat